PACE-AMR have opened their second funding round with up to £5 million available to support cutting-edge diagnostic projects.
The latest funding round will support a diverse portfolio of early-stage diagnostic projects, ranging from technical feasibility studies to early prototypes, across a range of technologies
PACE is particularly interested in proposals covering diagnostic tests for urinary tract, respiratory tract and bloodstream infections, and sepsis, as they represent the highest antibiotic consumption and burden from AMR.
A definitive list of what PACE seek is as follows:
- New in-vitro diagnostics in development at TRL stage 3-5 (late TRL 2 considered).
-
- Between Technical Feasibility and Early Prototype including field studies for generating data in relevant environment.
- Adaption of existing diagnostics that could be implemented in new healthcare settings/target regions/countries, or deployed for new indications/use-cases.
- Proposals that include potential for community care (e.g. pharmacy, care home, school, community diagnostic centre) or ‘at-home’ use.
- Analytes can be a direct measurement of bacterial markers or host-based biomarkers, or combination thereof.
- Applications providing solutions tailored to a intended setting. This includes those tailored towards resource-limited settings, including in low and middle income countries (LMICs).
The call closes on 30 October 2024.
You can find out more, including how to apply, here.
